Provided by Tiger Trade Technology Pte. Ltd.

Definium Therapeutics

36.90
+2.727.96%
Post-market: 36.65-0.2500-0.68%17:32 EDT
Volume:2.77M
Turnover:102.37M
Market Cap:4.96B
PE:-10.60
High:38.04
Open:34.85
Low:34.57
Close:34.18
52wk High:49.70
52wk Low:10.46
Shares:134.37M
Float Shares:129.97M
Volume Ratio:1.29
T/O Rate:2.13%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.4823
EPS(LYR):-2.0600
ROE:-64.09%
ROA:-20.64%
PB:5.40
PE(LYR):-17.91

Loading ...

Definium Therapeutics, Inc. Announces Proposed Public Offering

THOMSON REUTERS
·
Jun 23

Definium Therapeutics Is Maintained at Outperform by Leerink Partners

Dow Jones
·
Jun 23

Top Midday Gainers

MT Newswires Live
·
Jun 23

Canaccord ups Definium Therapeutics target to $60, calls DT120 ‘solid contender’

TIPRANKS
·
Jun 23

Definium Therapeutics rises 55.9%

TIPRANKS
·
Jun 23

RBC Capital Adjusts Price Target on Definium Therapeutics to $57 From $36, Maintains Outperform Rating

MT Newswires Live
·
Jun 23

Brisebois Raises Definium Therapeutics Price Target to $63 on Strong DT120 ODT Phase 3 Data and Reduced MDD/GAD Risk

TIPRANKS
·
Jun 22

Definium Therapeutics price target raised to $60 from $40 at Oppenheimer

TIPRANKS
·
Jun 22

Definium Therapeutics price target raised to $57 from $36 at RBC Capital

TIPRANKS
·
Jun 22

Definium Therapeutics Stock (DFTX) Rockets on a Phase 3 Trial Win

TIPRANKS
·
Jun 22

RBC Capital says would buy Definium Therapeutics after Phase III data

TIPRANKS
·
Jun 22

Definium Therapeutics DT120 data exceeds expectations, says Stifel

TIPRANKS
·
Jun 22

Definium Therapeutics Shares Jump on Strong Depression Drug Phase 3 Results

Dow Jones
·
Jun 22

Definium Therapeutics Reports Positive Phase 3 DT120 Results

TIPRANKS
·
Jun 22

BUZZ-U.S. STOCKS ON THE MOVE- Visteon, Incyte, Apogee

Reuters
·
Jun 22

BUZZ-Definium Therapeutics jumps as depression drug shows positive late-stage trial data

Reuters
·
Jun 22

Definium's LSD-based depression pill delivers strong late-stage results, shares surge

Reuters
·
Jun 22

Definium Therapeutics announces Emerge met primary endpoint

TIPRANKS
·
Jun 22

Definium Therapeutic Shares up 18.5% Premarket After Co's Lsd-Based Pill Reduces Depression Symptoms in Late-Stage Trial

THOMSON REUTERS
·
Jun 22

Definium Therapeutics - Phase 3 Emerge Study Meets Primary and All Key Secondary Efficacy Endpoints

THOMSON REUTERS
·
Jun 22